MST1 inhibits the progression of breast cancer by regulating the Hippo signaling pathway and may serve as a prognostic biomarker

Jin,Xiang; Zhu,Lihua; Xiao,Sheng; Cui,Zhuhong; Tang,Jing; Yu,Jiangyong; Xie,Mingjun

doi:10.3892/mmr.2021.12022

MST1 inhibits the progression of breast cancer by regulating the Hippo signaling pathway and may serve as a prognostic biomarker

Authors:
- Xiang Jin
- Lihua Zhu
- Sheng Xiao
- Zhuhong Cui
- Jing Tang
- Jiangyong Yu
- Mingjun Xie
View Affiliations

Affiliations: Department of Breast Surgery, The First People's Hospital of Yibin, Yibin, Sichuan 644000, P.R. China
Published online on: March 18, 2021 https://doi.org/10.3892/mmr.2021.12022
Article Number: 383
Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BCa) is the most common malignancy threatening the health of women worldwide, and the incidence rate has significantly increased in the last 10 years. Mammalian STE20‑like protein kinase 1 (MST1) is involved in the development of various types of malignant tumor. The present study aimed to investigate the role of MST1 in BCa and its potential involvement in the poor prognosis of patients with BCa. Reverse transcription‑quantitative PCR and immunohistochemistry were used to analyze the expression levels of MST1 in BCa, and the clinicopathological characteristics and prognosis of patients with BCa were further analyzed by statistical analysis. MST1 was overexpressed in BCa cell lines (MCF‑7, MDA‑MB‑231 and SKBR3). Cell Counting Kit‑8, 5‑ethynyl‑2'‑deoxyuridine and flow cytometry assays were used to analyze cell proliferation and apoptosis, respectively, and a wound healing assay was used to analyze cell migration. The results of the present study revealed that the downregulated expression levels of MST1 in BCa were closely associated with the poor prognosis of patients, and MST1 may be an independent risk factor for BCa. The overexpression of MST1 significantly inhibited the proliferation and migration, and promoted the apoptosis of BCa cells. In addition, the overexpression of MST1 significantly activated the Hippo signaling pathway. Treatment with XMU‑MP‑1 downregulated the expression levels of MST1 and partially reversed the inhibitory effects of MST1 on proliferation, migration and apoptosis‑related proteins, and inhibited the Hippo signaling pathway. In conclusion, the results of the present study suggested that MST1 expression levels may be downregulated in BCa and closely associated with tumor size and clinical stage, as well as the poor prognosis of affected patients. Furthermore, MST1 may inhibit the progression of BCa by targeting the Hippo signaling pathway.

View Figures

View References

1	Harbeck N and Gnant M: Breast cancer. Lancet. 18:1134–1150. 2017. View Article : Google Scholar
2	Britt KL, Cuzick J and Phillips KA: Key steps for effective breast cancer prevention. Nat Rev Cancer. 20:417–436. 2020. View Article : Google Scholar : PubMed/NCBI
3	McGuire A, Brown JA, Malone C, McLaughlin R and Kerin MJ: Effects of age on the detection and management of breast cancer. Cancers (Basel). 7:908–29. 2015. View Article : Google Scholar : PubMed/NCBI
4	Heer E, Harper A, Escandor N, Sung H, McCormack V and Fidler-Benaoudia MM: Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study. Lancet Glob Health. 8:e1027–e1037. 2020. View Article : Google Scholar : PubMed/NCBI
5	Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV and Mitsis M: Breast cancer in young Women: An overview. Updates Surg. 69:313–317. 2017. View Article : Google Scholar : PubMed/NCBI
6	Li Q, Liu J, Jiang Z and Liu Q: CSCO breast cancer guideline: Precise, economical and oriental. Sci China Life Sci. 63:1–3. 2020. View Article : Google Scholar : PubMed/NCBI
7	Winters S, Martin C, Murphy D and Shokar NK: Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 151:1–32. 2017. View Article : Google Scholar : PubMed/NCBI
8	Galan JA and Avruch J: MST1/MST2 Protein Kinases: Regulation and physiologic roles. Biochemistry. 55:5507–5519. 2016. View Article : Google Scholar : PubMed/NCBI
9	Hui OY, Zhou EX and Wang H: Mst1-Hippo pathway triggers breast cancer apoptosis via inducing mitochondrial fragmentation in a manner dependent on JNK-Drp1 axis. Onco Targets Ther. 12:1147–1159. 2019. View Article : Google Scholar : PubMed/NCBI
10	Harvey KF, Zhang X and Thomas DM: The Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013. View Article : Google Scholar : PubMed/NCBI
11	Hong AW, Meng Z and Guan KL: The Hippo pathway in intestinal regeneration and disease. Nat Rev Gastroenterol Hepatol. 13:324–337. 2016. View Article : Google Scholar : PubMed/NCBI
12	Torres-Bacete J, Delgado-Martin C, Gomez-Moreira C, Simizu S and Rodríguez-Fernández JL: The mammalian sterile 20-like 1 kinase controls selective CCR7-dependent functions in human dendritic cells. J Immunol. 195:973–81. 2015. View Article : Google Scholar : PubMed/NCBI
13	Zhang M, Zhang L, Hu J, Lin J, Wang T, Duan Y, Man W, Feng J, Sun L, Jia H, et al: MST1 coordinately regulates autophagy and apoptosis in diabetic cardiomyopathy in mice. Diabetologia. 59:2435–2447. 2016. View Article : Google Scholar : PubMed/NCBI
14	Zhao WB, Lu Q, Nguyen MN, Su Y, Ziemann M, Wang LN, Kiriazis H, Puthalakath H, Sadoshima J, Hu HY and Du XJ: Stimulation of β-adrenoceptors up-regulates cardiac expression of galectin-3 and BIM through the hippo signalling pathway. Br J Pharmacol. 176:2465–2481. 2019. View Article : Google Scholar : PubMed/NCBI
15	Singh A, Ramesh S, Cibi DM, Yun LS, Li J, Li L, Manderfield LJ, Olson EN, Epstein JA and Singh MK: Hippo signaling mediators yap and taz are required in the epicardium for coronary vascµl ature development. Cell Rep. 15:1384–1393. 2016. View Article : Google Scholar : PubMed/NCBI
16	Yu FX, Zhao B and Guan KL: Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 163:811–828. 2015. View Article : Google Scholar : PubMed/NCBI
17	Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, Sudol M, Herlyn M and Mauviel A: Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol. 134:123–132. 2014. View Article : Google Scholar : PubMed/NCBI
18	He M, Zhou Z, Shah AA, Hong Y, Chen Q and Wan Y: New insights into posttranslational modifications of Hippo pathway in carcinogenesis and therapeutics. Cell Div. 11:42016. View Article : Google Scholar : PubMed/NCBI
19	Vincent-Mistiaen Z, Elbediwy A, Vanyai H, Cotton J, Stamp G, Nye E, Spencer-Dene B, Thomas GJ, Mao J and Thompson B: YAP drives cutaneous squamous cell carcinoma formation and progression. Elife. 7:e333042018. View Article : Google Scholar : PubMed/NCBI
20	Maugeri-Saccà M and De Maria R: Hippo pathway and breast cancer stem cells. Crit Rev Oncol Hematol. 99:115–122. 2016. View Article : Google Scholar : PubMed/NCBI
21	Rodriguez D, Ramkairsingh M, Lin X, Kapoor A, Major P and Tang D: The central contributions of breast cancer stem cells in developing resistance to endocrine therapy in estrogen receptor (ER)-positive breast cancer. Cancers (Basel). 11:10282019. View Article : Google Scholar
22	Cortes E, Lachowski D, Rice A, Thorpe SD, Robinson B, Yeldag G, Lee DA, Ghemtio L, Rombouts K and Del Río Hernández AE: Tamoxifen mechanically deactivates hepatic stellate cells via the G protein-coupled estrogen receptor. Oncogene. 38:2910–2922. 2019. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Kolak A, Kamińska M, Sygit K, Budny A, Surdyka D, Kukiełka-Budny B and Burdan F: Primary and secondary prevention of breast cancer. Ann Agric Environ Med. 24:549–553. 2017. View Article : Google Scholar : PubMed/NCBI
25	Hosonaga M, Saya H and Arima Y: Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis Rev. 39:711–720. 2020. View Article : Google Scholar : PubMed/NCBI
26	Siegel RL, Miller KD and Jemal A: Cancer statistics. 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
27	McDonald ES, Clark AS, Tchou J, Zhang P and Freedman GM: Clinical diagnosis and management of breast cancer. J Nucl Med. 57 (Suppl 1):9S–16S. 2016. View Article : Google Scholar : PubMed/NCBI
28	Kim MK, Jang JW and Bae SC: DNA binding partners of YAP/TAZ. BMB Rep. 51:126–133. 2018. View Article : Google Scholar : PubMed/NCBI
29	He Z, Zhao TT, Jin F, Li JG, Xu YY, Dong HT, Liu Q, Xing P, Zhu GL, Xu H and Miao ZF: Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling. Biochem Biophys Res Commun. 503:2340–2347. 2018. View Article : Google Scholar : PubMed/NCBI
30	Li JA, Kuang T, Pu N, Fang Y, Han X, Zhang L, Xu X, Wu W, Wang D, Lou W and Rong Y: TRAF6 Regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer. Clin Exp Med. 19:211–218. 2019. View Article : Google Scholar : PubMed/NCBI
31	Lin XY, Cai FF, Wang MH, Pan X, Wang F, Cai L, Cui RR, Chen S and Biskup E: Mammalian sterile 20-like kinase 1 expression and its prognostic significance in patients with breast cancer. Oncol Lett. 14:5457–5463. 2017.PubMed/NCBI
32	Zhou J and Che Q: Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway. FASEB J. 33:3420–3436. 2019. View Article : Google Scholar : PubMed/NCBI
33	Turunen SP, Nandelstadh PV, Öhman T, Gucciardo E, Seashore-Ludlow B, Martins B, Rantanen V, Li H, Höpfner K, Östling P, et al: FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis. Cell Death Differ. 26:2577–2593. 2019. View Article : Google Scholar : PubMed/NCBI
34	Buccitelli C and Selbach M: mRNAs, proteins and the emerging principles of gene expression control. Nat Rev Genet. 21:630–644. 2020. View Article : Google Scholar : PubMed/NCBI
35	Kulkarni A, Chang MT, Vissers JHA, Dey A and Harvey KF: The hippo pathway as a driver of select human cancers. Trends Cancer. 6:781–796. 2020. View Article : Google Scholar : PubMed/NCBI
36	Zheng Y and Pan D: The hippo signaling pathway in development and disease. Dev Cell. 50:264–282. 2019. View Article : Google Scholar : PubMed/NCBI
37	Tao Y, Cai F, Shan L, Jiang H, Ma L and Yu Y: The hippo signaling pathway: An emerging anti-cancer drug target. Discov Med. 24:7–18. 2017.PubMed/NCBI
38	Wu H, Zhang W, Wu Z, Liu Y, Shi Y, Gong J, Shen W and Liu C: miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma. Cell Death Dis. 10:482019. View Article : Google Scholar : PubMed/NCBI
39	Han Q, Lin X, Zhang X, Jiang G, Zhang Y, Miao Y, Rong X, Zheng X, Han Y, Han X, et al: WWC3 regulates the Wnt and hippo pathways via dishevelled proteins and large tumour suppressor 1, to suppress lung cancer invasion and metastasis. J Pathol. 242:435–447. 2017. View Article : Google Scholar : PubMed/NCBI
40	Fan F, He Z, Kong LL, Chen Q, Yuan Q, Zhang S, Ye J, Liu H, Sun X, Geng J, et al: Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci Transl Med. 8:352ra1082016. View Article : Google Scholar : PubMed/NCBI